News articles about Thermo Fisher Scientific (NYSE:TMO) have trended positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Thermo Fisher Scientific earned a news impact score of 0.25 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.6083471423839 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Thermo Fisher Scientific Inc (TMO) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Thermo Fisher Scientific : Medical Research Stock Performance Review — Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher Scientific (4-traders.com)
- Jefferies Group Research Analysts Raise Earnings Estimates for Thermo Fisher Scientific Inc (TMO) (americanbankingnews.com)
- With a Healthy CAGR of 8.1%, Mass Spectrometer Market to Reach US $9.99 Bn by 2024 (sbwire.com)
- Thermo Fisher Scientific : Measurement of Autoantibodies (4-traders.com)
Thermo Fisher Scientific (NYSE:TMO) traded down 1.17% during mid-day trading on Tuesday, reaching $189.62. 1,215,530 shares of the company’s stock traded hands. The stock has a market capitalization of $73.97 billion, a PE ratio of 33.03 and a beta of 1.05. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $194.30. The stock’s 50 day moving average is $181.07 and its 200-day moving average is $171.15.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter last year, the company earned $2.03 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts anticipate that Thermo Fisher Scientific will post $9.35 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. The ex-dividend date is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.
TMO has been the subject of several recent research reports. Bank of America Corporation restated a “buy” rating and issued a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Citigroup Inc. reiterated a “buy” rating and set a $201.00 price objective (up previously from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. BidaskClub lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Deutsche Bank AG set a $200.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Saturday, June 10th. Two equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $193.56.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.chaffeybreeze.com/2017/09/19/thermo-fisher-scientific-tmo-receives-daily-news-impact-score-of-0-25.html.
In other Thermo Fisher Scientific news, Director Jim P. Manzi sold 11,318 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total transaction of $1,957,334.92. Following the sale, the director now owns 38,757 shares of the company’s stock, valued at $6,702,635.58. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now directly owns 25,518 shares in the company, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,738 shares of company stock worth $4,021,512. 0.49% of the stock is owned by corporate insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.